Skip to content

Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower

Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00663325
Enrollment
30
Registered
2008-04-22
Start date
2007-12-31
Completion date
Unknown
Last updated
2009-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hygiene

Brief summary

The purpose of this study is to demonstrate the safety of the gynecological formulation in normal and usual usage condition of Dermacyd Tina Gel Sweet Flower.

Interventions

Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.

Sponsors

Sanofi
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
10 Years to 20 Years
Healthy volunteers
Yes

Inclusion criteria

* Integral skin test in the region;

Exclusion criteria

* Lactation or gestational risk or gestation; * Use of Anti-inflammatory or immunosuppression drugs 1 month before the study; * Topical medication use at the region to be treated; * Cutaneous disease or active gynecological disease which may interfere in study results; * Personal history of allergic disease at the area to be treated; * Allergic or atopic history; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Design outcomes

Primary

MeasureTime frame
Adverse events and their intensity and their association with the treatment21 days

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026